📊 Key Data
  • ASC37 Half-Life: 372 hours (15.5 days) in non-human primates, 6.4x longer than retatrutide.
  • ASC30_48 FDC Weight Reduction: 10.5% in cynomolgus monkeys over 8 days.
  • Market Potential: Obesity market projected to exceed $100 billion by 2030.
🎯 Expert Consensus

Experts would likely conclude that Ascletis's innovative pipeline, combining ultra-long-acting injectables and oral dual agonists, positions the company as a formidable disruptor in the evolving obesity treatment landscape, though clinical validation remains critical.

about 4 hours ago
Beyond the Weekly Jab: Ascletis Unveils Next-Gen Obesity Drug Pipeline

Beyond the Weekly Jab: Ascletis Unveils Next-Gen Obesity Drug Pipeline

WASHINGTON, D.C. – November 16, 2026 — The GLP-1 gold rush is maturing. For the past three years, the biopharmaceutical industry has been locked in a frantic scramble to prove baseline efficacy in weight management. But as we walk the floor at ObesityWeek 2026 in Washington, D.C., it is abundantly clear that the battle lines have shifted. The new frontiers are not just about how much weight a patient can lose, but how seamlessly that therapy can be integrated into their daily life.

The era of the weekly injection, currently dominated by pharmaceutical titans, may soon look as antiquated as the dial-up modem. Enter Ascletis Pharma Inc., a Hong Kong-listed clinical-stage biopharmaceutical company that is aggressively positioning itself to disrupt the next wave of metabolic therapeutics. Originally known for its antiviral portfolio, the company has executed a strategic pivot toward metabolic diseases, leveraging proprietary artificial intelligence and advanced delivery platforms.

At this year's conference, Ascletis presented compelling preclinical data for two distinct candidates that address the market's biggest vulnerabilities: patient adherence and supply chain scalability. By showcasing a highly potent once-daily oral combination pill and an ultra-long-acting triple agonist designed for quarterly injections, the company is signaling that the "security-first" mindset of modern pharma is evolving. Today, corporate strategy dictates that true market security lies in overcoming the logistical and behavioral barriers of current standard-of-care treatments.

Challenging the Weekly Needle with Ultra-Long-Acting Peptides

The most striking data to emerge from Ascletis's presentations centers on ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist. While dual agonists like tirzepatide and emerging triple agonists like retatrutide have set high watermarks for clinical efficacy, they remain tethered to a once-weekly subcutaneous injection schedule. This frequency presents ongoing challenges for long-term patient adherence and places immense strain on global cold-chain manufacturing and auto-injector supply lines.

ASC37 is designed to break this cycle. Utilizing the company's proprietary Ultra-Long-Acting Platform (ULAP) to create a self-assembly lipid depot, the drug demonstrated an astonishing elimination half-life of 372 hours (15.5 days) in non-human primates. To put this in perspective, this is approximately 6.4 times longer than the 57.8-hour half-life observed for retatrutide in similar models.

"The chemistry required to stabilize a peptide for a month, let alone a quarter, without causing severe injection-site reactions or initial burst-release toxicity is notoriously complex," noted an independent pharmacology specialist reviewing the poster data. "If these lipid depot formulations hold up in human pharmacokinetics, we are looking at a paradigm shift from a weekly chore to a quarterly clinical visit."

The potency data is equally aggressive. In vitro assays using INS-1 832/3 cells revealed that ASC37 achieved an EC50 of 0.9858 nM for insulin secretion, representing a 23.4-fold higher potency compared to retatrutide. In diet-induced obese mice, daily subcutaneous administration of ASC37 led to a dose-dependent weight loss reaching up to 41.5% at Day 12 at the highest tested dose. Crucially, Ascletis aims to achieve this with an injection volume of no more than 1 mL, a critical metric for patient comfort.

The Pill Revolution and the Race for Oral Dual Agonists

While ultra-long-acting injectables address one end of the patient preference spectrum, the other end is entirely focused on the pill. The holy grail of the obesity market—projected by analysts to exceed $100 billion by 2030—is a highly effective, well-tolerated, once-daily oral medication.

Current oral options are limited. Novo Nordisk's oral semaglutide requires strict fasting protocols to ensure absorption, while Eli Lilly's orforglipron, a true small molecule, has shown great promise but targets only the GLP-1 receptor. Ascletis is attempting to leapfrog the competition with ASC30_48 FDC, an in-house developed fixed-dose combination targeting both GLP-1R and GIPR.

The data presented in Washington outlines a compelling pharmacological profile. The ASC48 component, a selective GIPR agonist, demonstrated an in vitro EC50 of 1 pM—notably more potent than tirzepatide's 3 pM in the same assay. Furthermore, ASC48 exhibited robust oral bioavailability in non-human primates, boasting a half-life of 16.2 hours, which comfortably supports a once-daily regimen.

When combined with ASC30, the synergistic effects were profound. In an 8-day randomized study in cynomolgus monkeys, the ASC30_48 FDC cohort achieved a 10.5% reduction in body weight. This compared favorably to a 6.9% reduction for ASC30 monotherapy and a 1.7% reduction for ASC48 alone. The combination effectively delivered a 52% relative improvement over the single-receptor approach.

From a business intelligence standpoint, oral small molecules represent a massive commercial advantage. They bypass the complex, expensive biologic manufacturing processes and the global shortage of sterile fill-finish capacity that has plagued injectable weight-loss drugs. If Ascletis can successfully translate this dual-agonist efficacy into a simple daily pill, it could democratize access to next-generation obesity care.

From Preclinical Promise to Clinical Reality

As with all preclinical data, rigorous skepticism is the cornerstone of sound analysis. The rapid, acute weight loss observed in non-human primates over an 8-day period provides excellent proof of mechanism, but it is not a guaranteed proxy for long-term human efficacy and safety. The gastrointestinal tolerability of highly potent oral dual agonists remains a significant hurdle that can only be cleared through extensive Phase II and Phase III trials.

However, Ascletis is not merely a preclinical laboratory; it is a clinical-stage engine. The company's lead program, ASC30 (a once-daily oral GLP-1R agonist), is already being evaluated in two global Phase III studies for obesity. Furthermore, the ULAP technology underpinning the long-acting ASC37 is actively being tested in human trials for other pipeline candidates, including the amylin receptor agonist ASC36, which recently initiated Phase I studies in the United States.

This parallel clinical advancement significantly de-risks the underlying delivery platforms. Ascletis has announced that it expects to submit an Investigational New Drug (IND) application for the ASC30_48 FDC to the U.S. FDA in the fourth quarter of 2026. Given the maturity of the preclinical package presented at ObesityWeek, an IND for ASC37 is likely to follow shortly after.

Market Implications in a $100 Billion Arena

The financial markets have historically treated the obesity sector as a two-horse race, but the sheer size of the total addressable market demands a broader ecosystem of therapeutic options. Currently, Ascletis trades with cautious optimism; analysts maintain a "Hold" rating with a target price hovering around HK$13.86, largely because the market requires human safety and efficacy data to justify a major valuation inflection.

Yet, the strategic positioning is undeniable. By utilizing its proprietary Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) platform, Ascletis has rapidly assembled a wholly owned pipeline of 15 differentiated assets. In an environment where major pharmaceutical companies are desperate to replenish their metabolic pipelines ahead of upcoming patent cliffs, a company holding the keys to both oral multi-agonists and ultra-long-acting depot formulations becomes a prime target for lucrative licensing deals or strategic partnerships.

The narrative emerging from ObesityWeek 2026 is clear. The next phase of the metabolic disease market will not be won simply by suppressing appetite, but by mastering the pharmacokinetics of convenience. Whether through a daily pill that mimics the efficacy of a dual-agonist injection, or a quarterly shot that frees patients from the burden of weekly adherence, Ascletis Pharma is proving that the future of obesity management will be defined by those who can engineer elegance into efficacy.

Topics & Related

Event:
Clinical & Scientific
Theme:
Drug Development
Sector:
Pharmaceuticals
Product:
GLP-1/Weight Loss

📝 This article is still being updated

Are you a relevant expert who could contribute your opinion or insights to this article? We'd love to hear from you. We will give you full credit for your contribution.

Contribute Your Expertise →
UAID: 55022